Anhui Huaheng Biotechnology Balance Sheet Health
Financial Health criteria checks 3/6
Anhui Huaheng Biotechnology has a total shareholder equity of CN¥1.8B and total debt of CN¥1.2B, which brings its debt-to-equity ratio to 68.3%. Its total assets and total liabilities are CN¥4.0B and CN¥2.1B respectively. Anhui Huaheng Biotechnology's EBIT is CN¥490.4M making its interest coverage ratio 103.7. It has cash and short-term investments of CN¥353.0M.
Key information
68.3%
Debt to equity ratio
CN¥1.25b
Debt
Interest coverage ratio | 103.7x |
Cash | CN¥352.98m |
Equity | CN¥1.83b |
Total liabilities | CN¥2.14b |
Total assets | CN¥3.97b |
Recent financial health updates
Recent updates
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jul 22Anhui Huaheng Biotechnology Co., Ltd.'s (SHSE:688639) Intrinsic Value Is Potentially 43% Above Its Share Price
Jul 12Is Anhui Huaheng Biotechnology (SHSE:688639) Using Too Much Debt?
Jun 21Take Care Before Jumping Onto Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Even Though It's 27% Cheaper
Jun 05We Ran A Stock Scan For Earnings Growth And Anhui Huaheng Biotechnology (SHSE:688639) Passed With Ease
May 12Earnings Report: Anhui Huaheng Biotechnology Co., Ltd. Missed Revenue Estimates By 37%
Apr 23Anhui Huaheng Biotechnology Co., Ltd.'s (SHSE:688639) Business Is Trailing The Market But Its Shares Aren't
Mar 18Financial Position Analysis
Short Term Liabilities: 688639's short term assets (CN¥1.1B) do not cover its short term liabilities (CN¥1.7B).
Long Term Liabilities: 688639's short term assets (CN¥1.1B) exceed its long term liabilities (CN¥468.1M).
Debt to Equity History and Analysis
Debt Level: 688639's net debt to equity ratio (49%) is considered high.
Reducing Debt: 688639's debt to equity ratio has increased from 32.2% to 68.3% over the past 5 years.
Debt Coverage: 688639's debt is well covered by operating cash flow (24.2%).
Interest Coverage: 688639's interest payments on its debt are well covered by EBIT (103.7x coverage).